Roche Weighs Divestment of Cancer Data Startup, FT Reports
Provided by
Dow Jones
--Roche is considering divesting or partially selling its U.S. cancer data specialist Flatiron Health, the Financial Times reports, citing unnamed sources.
--Flatiron's ownership by the Swiss pharma giant, although a separate legal entity, limited the startup's ability to partner with rivals and weighed on sales, according to the FT.
--Many Roche executives who initially supported the deal have left the company, resulting in reduced internal support for Flatiron, the FT reports.
-- Roche declined to comment when approached by Dow Jones Newswires.
Full story: https://bit.ly/4d7HPlk
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
August 07, 2024 03:03 ET (07:03 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
United States